New hope for elderly leukemia patients: drug combo shows promise
NCT ID NCT03466294
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, azacitidine and venetoclax, in 42 elderly patients (age 60+) with newly diagnosed acute myeloid leukemia (AML) who could not have standard chemotherapy. The treatment was given as an initial 'induction' phase, followed by a 'maintenance' phase with venetoclax alone for those who responded well. The goal was to see how long patients stayed in remission and how many achieved a deep response with no detectable cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
azacitidine and venetoclax
What this could lead to
If successful, this combination could offer a more effective, less toxic treatment option for elderly AML patients who cannot tolerate standard chemotherapy.
What could go wrong
This is a small, phase 2 study with only 42 participants. Results may not apply to all patients, and side effects like low blood counts or infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Colorado Denver
Aurora, Colorado, 80045, United States